Versailles

Researchers are evaluating a multimodal music therapy intervention called AMUSED to see if it can improve engagement and reduce behavioral symptoms in older adults with severe dementia living in care facilities. This pilot randomized clinical trial aims to test the study design, identify the best outcome measures for behavioral symptoms, and assess if speech can indicate treatment effectiveness. The study compares music therapy with a reading activity to determine which leads to greater improvements in behavior and speech patterns. Participants will join group sessions twice a week for 12 weeks, each lasting 40 minutes between lunch and dinner. The music therapy involves live, participant-preferred music with singing, touch, and rhythmic instrument playing led by a certified music therapist. The comparison group will participate in reading sessions with stories and discussions led by a trained assistant, following the same schedule and structure but without music. Each small group will work consistently with the same therapist or reader throughout the study. During the study, participants will be observed and assessed multiple times for behavioral symptoms, cognition, and speech, including a follow-up four weeks after treatment ends. Researchers will measure changes in dementia-related behaviors and speech patterns to evaluate the intervention's impact. The study focuses on feasibility, outcome measures, and obtaining preliminary data on the lasting effects of the music therapy intervention over a total participation period of 12 weeks plus follow-up.

Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3, randomized, placebo-controlled study to see if it can reduce the risk of major adverse cardiovascular events (MACE-PLUS) in adults with established atherosclerotic cardiovascular disease (ASCVD) or those at high risk for a first ASCVD event. The study compares AZD0780 to a placebo and monitors participants from randomization until the primary analysis censoring date, followed by a final study closure visit. Participants will be randomly assigned to receive either oral AZD0780 or an oral placebo once daily. The treatment period lasts until the primary analysis censoring date, after which a study closure visit will occur. The study is event-driven and designed to assess the time to the first major cardiovascular event during treatment. During the study, participants will be closely monitored with various assessments to evaluate cardiovascular outcomes and safety over approximately 54 months. Researchers will track the time to first event of any component of MACE-PLUS and collect data to assess the effect of AZD0780 compared to placebo. The study includes regular visits and evaluations to ensure participant safety and adherence to treatment.

Researchers are evaluating whether the drug zilebesiran can reduce the risk of major cardiovascular events such as cardiovascular death, nonfatal heart attacks, strokes, or heart failure in adults who have hypertension that is not well controlled and who either have established cardiovascular disease or are at high risk for it. This Phase 3 global study is designed to continue until enough cardiovascular events have occurred to assess the treatment's effect. Participants will be randomly assigned to receive either zilebesiran or a placebo, both given as injections under the skin (subcutaneous administration). All participants will continue with their standard care, which includes treatment with at least two antihypertensive medications, one of which must be a diuretic such as a thiazide or loop diuretic. The study is double-blind, so neither participants nor researchers know who is receiving the active drug or placebo. During the study, participants will be closely monitored for cardiovascular events including heart attacks, strokes, heart failure hospitalizations, and cardiovascular deaths over approximately five years. Researchers will collect data on these events to determine the time until the first occurrence of any of these outcomes. Safety assessments and standard clinical evaluations will also be performed throughout the study period to ensure participant well-being.